Breaking
AI-designed TEAD inhibitor shows tumor shrinkage
Recovery Mode

AI-designed TEAD inhibitor shows tumor shrinkage

Olivia Gagnon · November 10, 2026

Insilico Medicine’s AI-designed TEAD inhibitor ISM6331 shows 18.2% response rate in mesothelioma patients, with 68.2% achieving disease control in early trials.

★

Longevity Lab

Longevity Lab →
Hepatitis C drug shows promise but misses key patient groups
Longevity Lab

Hepatitis C drug shows promise but misses key patient groups

AbbVie’s Maviret achieves 96% cure rate for acute hepatitis C but excludes key patient groups, raising access and efficacy concerns in real-world…

+

More News

AI-designed TEAD inhibitor shows tumor shrinkage
Recovery Mode

Insilico Medicine’s AI-designed TEAD inhibitor ISM6331 shows 18.2% response rate in mesothelioma patients, with 68.2% achieving disease control…

November 10, 2026
Hepatitis C drug shows promise but misses key patient groups
Longevity Lab

AbbVie’s Maviret achieves 96% cure rate for acute hepatitis C but excludes key patient groups, raising access and…

November 9, 2026
Moderna Merck seek approval for melanoma vaccine
Recovery Mode

Moderna and Merck are seeking approval for intismeran autogene, a melanoma vaccine, after their November 6 earnings release,…

November 7, 2026
Trump pressures Europe on drug prices, delays launches
Mind Matters

Trump pressures Europe to cut drug prices, while his administration delays new launches, as a March 2026 poll…

November 6, 2026
FDA approves first DNA-based HPV treatment with delivery device concerns
Longevity Lab

FDA approves Voceryq, the first DNA-based immunotherapy for HPV-driven recurrent respiratory papillomatosis (RRP), offering hope for patients avoiding…

November 5, 2026
Generic manufacturers shift focus to reliability
Gut Check

Generic manufacturers may shift focus to reliability due to supply chain issues and price pressure affecting the industry.

November 4, 2026
Fresenius expands biosimilars portfolio in big deal
Mind Matters

Fresenius expands biosimilars portfolio through big deal with WuXi Biologics, gaining option rights on up to 37 candidates.

November 3, 2026
Germany’s AfD softens anti euro stance
Recovery Mode

Germany's AfD softens anti euro stance ahead of national government hopes. Explore the party's strategic shift and political…

November 2, 2026
Democrats win Congress but Trump veto looms
Recovery Mode

Trump veto looms as Democrats win Congress, sparking fresh trade hurdles, oversight hearings and plans to roll back…

November 1, 2026
France Deploys 70,000 Police to Contain Escalating Protests
Recovery Mode

France deploys 70,000 police to contain nationwide protests over living costs and government policies, following recent riots and…

October 31, 2026